News & Events about Taysha Gene Therapies Inc.
Taysha Gene Therapies (NASDAQ:TSHA Get Rating) had its price objective decreased by Truist Financial from $15.00 to $4.00 in a report released on Wednesday, The Fly reports. Truist Financial currently has a buy rating on the stock. Several other analysts have also weighed in on the company. ...
Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? PR Newswire NEW YORK, Oct. 25, 2022 NEW YORK, Oct. 25, 2022...
Ticker Report
5 months ago
Taysha Gene Therapies (NASDAQ:TSHA Get Rating) had its price objective cut by research analysts at Chardan Capital from $34.00 to $32.00 in a research report issued on Friday, Marketbeat Ratings reports. The brokerage presently has a buy rating on the stock. Several other ...
Taysha Gene Therapies (NASDAQ:TSHA Get Rating) and Gamida Cell (NASDAQ:GMDA Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst ...
Globe Newswire
8 months ago
The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ETDALLAS, June 13, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of ...